About Pricing FAQs Providers Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

COMPLETEDPhase 1/2NCT00726648

CDP323 Biomarker Study

Comparison of the effects of different CDP323 doses given over a period of four weeks on blood biomarkers in subjects with relapsing forms of multiple sclerosis.

Lead sponsor: UCB Pharma•2 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

UCB Pharma

Collaborators

Biogen

Age

18 - 65 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Female and male subjects aged 18-65 years
•Relapsing form of MS with at least one clinical relapse in the 24 months before screening;
•Screening EDSS score of 0-6.5;
•Must be fully immunocompetent
•Female subjects of childbearing potential must agree to practice contraception methods

Exclusion Criteria

•Any conditions that could interfere with the contrast-enhanced MRI;
•Any clinically significant disease state or findings other than MS;
•Any clinically significant deviation from the pre-defined ranges for laboratory tests;
•Concomitant treatment with MS disease modifying drugs

Related studies

A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)

NCT06433752 · Relapsing Multiple Sclerosis, Multiple Sclerosis

RECRUITINGPhase 3

Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.

NCT06846281 · Relapsing Multiple Sclerosis

RECRUITINGPhase 3

Comparative PK, PD, Efficacy, and Safety Assessment of the Proposed Ocrelizumab Biosimilar CYB704 and Ocrevus in Participants With Relapsing Multiple Sclerosis

NCT06847724 · Relapsing Multiple Sclerosis

A NIS Evaluating Various Injectable and Oral Treatments in Patients With Relapsing Multiple Sclerosis

NCT05344469 · Relapsing Multiple Sclerosis

Cognitive Performance, Sleep Disturbances and Fatigue in Multiple Sclerosis

NCT07426991 · Multiple Sclerosis, Remitting-Relapsing Multiple Sclerosis, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: September 12, 2011Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE1/PHASE2

Enrollment71

Start dateJul 2008

Last updatedSep 12, 2011

Condition

Relapsing Multiple Sclerosis

Locations shown

Tooting, London

Croydon, Surrey

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 12, 2011Data synced to Clareo: July 13, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions